Form 4: Edgewise Therapeutics CSO Alan J. Russell Reports Stock Transactions
SEC Form 4 Filing
Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, reports the acquisition and disposal of company stock, including shares acquired through restricted stock units and sales to cover tax obligations.
Summary
- On May 1, 2024, Alan J. Russell, the Chief Scientific Officer of Edgewise Therapeutics, acquired 5,208 shares of common stock at $0.00 and disposed of 1,576 shares at an average price of $18.91 on May 2, 2024.
- These transactions involved the vesting of Restricted Stock Units (RSUs) and a sale to cover statutory tax withholding obligations.
- Following these transactions, Russell directly owns 7,238 shares of common stock and 5,209 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and related to compensation. There is no indication of unusual activity or significant change in ownership.
Positives
- The acquisition of shares through RSU vesting indicates confidence in the company's future performance.
Negatives
- The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it is a common practice.
Risks
- The market's reaction to insider sales, even for tax purposes, can be unpredictable and may temporarily affect the stock price.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Sell-to-cover transactions are a common practice among executives receiving equity compensation, and the number of shares sold is generally proportional to the tax obligations incurred.
- The vesting schedule of the RSUs (three equal annual installments) is a typical arrangement for employee equity grants.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- Transparency in insider transactions helps maintain investor confidence.
Key Dates
| Date | Description |
|---|---|
| May 15, 2023 | 2,968 shares purchased pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| May 1, 2023 | RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. |
| November 15, 2024 | 2,088 shares purchased pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| May 1, 2024 | Acquisition of 5,208 shares of common stock through RSU vesting. |
| May 2, 2024 | Sale of 1,576 shares to cover tax obligations. |
| May 3, 2024 | Date of signature for the Form 4 filing. |
| May 1, 2032 | Expiration date of Restricted Stock Units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.